Results 11 to 20 of about 145,187 (366)

Western diet contributes to the pathogenesis of non-alcoholic steatohepatitis in male mice via remodeling gut microbiota and increasing production of 2-oleoylglycerol

Nature Communications, 2023
The interplay between western diet and gut microbiota drives the development of non-alcoholic fatty liver disease and its progression to non-alcoholic steatohepatitis.
Ming Yang, Xiaoqiang Qi, Nan Li, Jussuf T. Kaifi, Shiyou Chen, Andrew A. Wheeler, Eric T. Kimchi, Aaron C. Ericsson, R. Scott Rector, Kevin F. Staveley-O’Carroll, Guangfu Li   +10 more
doaj   +2 more sources

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

The Lancet, 2015
Matthew J. Armstrong, Piers Gaunt, Guruprasad P. Aithal, Darren Barton, Diana Hull, Richard Parker, Jonathan Hazlehurst, Kathy Guo, George Abouda, Mark Aldersley, Deborah Stocken, Stephen Gough, Jeremy Tomlinson, Rachel M. Brown, Stefan G. Hübscher, Philip N. Newsome   +15 more
openalex   +3 more sources

MACROPHAGE-DERIVED OSTEOPONTIN (SPP1) PROTECTS FROM NON-ALCOHOLIC STEATOHEPATITIS.

Gastroenterology, 2023
BACKGROUND & AIMS Non-alcoholic steatohepatitis (NASH) is characterized by steatosis, lobular inflammation, hepatocyte ballooning degeneration and fibrosis, all of which increase the risk of progression to end-stage liver disease. Osteopontin (OPN, SPP1)
Hui-Jing Han, X. Ge, Sai Santosh Babu Komakula, R. Desert, Sukanta Das, Zhuolun Song, Wei Chen, Dipti Athavale, H. Gaskell, Daniel Lantvit, G. Guzman, N. Nieto   +11 more
semanticscholar   +1 more source

Resmetirom: An Orally Administered, Smallmolecule, Liver-directed, β-selective THR Agonist for the Treatment of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis

touchREVIEWS in Endocrinology, 2023
Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of fatty liver disease, including non-alcoholic fatty liver (NAFL) and its more progressive form, non-alcoholic steatohepatitis (NASH).
Gres Karim, M. Bansal
semanticscholar   +1 more source

Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis

Nature Medicine, 2023
There are no approved diagnostic biomarkers for at-risk non-alcoholic steatohepatitis (NASH), defined by the presence of NASH, high histological activity and fibrosis stage ≥2, which is associated with higher incidence of liver-related events and ...
Arun J. Sanyal, Sudha S. Shankar, Katherine P. Yates, James A. Bolognese, Erika Daly, Clayton A. Dehn, B. Neuschwander‐Tetri, Kris V. Kowdley, R. Vuppalanchi, Cynthia Behling, J. Tonascia, Anthony Samir, C. Sirlin, Sarah P Sherlock, Kathryn J. Fowler, Helen Heymann, Tania N. Kamphaus, R. Loomba, Roberto A Calle   +18 more
semanticscholar   +1 more source

Treatments for NAFLD [PDF]

Farmacja Polska, 2021
Non-alcoholic fatty liver disease (NAFLD) is categorised into simple steatosis, termed nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH).
Katarzyna Juszczyńska
doaj   +1 more source

Non-alcoholic Steatohepatitis

Medicine, 2002
Abstract The term ‘non-alcoholic steatohepatitis' (NASH) was introduced in 1980 to define a condition that is histologically similar to alcoholic liver disease but in which alcohol has no part and that is most commonly associated with obesity and/or type 2 diabetes. The condition can lead to cirrhosis and hepatocellular cancer.
H, Zantout, K, Barada
  +8 more sources

Metabolomic Predictors of Non-alcoholic Steatohepatitis and Advanced Fibrosis in Children

Frontiers in Microbiology, 2021
Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease in western countries both in children and adults. Metabolic dysregulation associated with gut microbial dysbiosis may influence disease progression from hepatic ...
Kattayoun Kordy, Kattayoun Kordy, Fan Li, David J. Lee, Jason M. Kinchen, Michael H. Jew, Maria Eduarda La Rocque, Sara Zabih, Monica Saavedra, Cora Woodward, Nicole J. Cunningham, Nicole H. Tobin, Grace M. Aldrovandi   +12 more
doaj   +1 more source

Immune cell-mediated features of non-alcoholic steatohepatitis

Nature reviews. Immunology, 2021
Non-alcoholic fatty liver disease (NAFLD) includes a range of hepatic manifestations, starting with liver steatosis and potentially evolving towards non-alcoholic steatohepatitis (NASH), cirrhosis or even hepatocellular carcinoma. NAFLD is a major health
T. Huby, E. Gautier
semanticscholar   +1 more source

Structure of anaemic conditions comorbid to alcoholic and non-alcoholic steatohepatitis

Journal of Education, Health and Sport, 2021
The retrospective analysis of 378 medical records of inpatients with steatohepatitis (SH) depending on its etiology was performed to identify and study the type of anaemic conditions (AC).
Oksana Khukhlina, Tetiana Antofiichuk, Mykola Antofiichuk   +2 more
doaj   +1 more source